Comprehensive Pharmacogenomics

Pharmacogenomics

Many pills and tablets on black background for decorate and design project.

Comprehensive Pharmacogenomics

Preemptive or reactive genotyping of patients for pharmacogenomic purposes to provide an assessment for 30 genes with strong drug-gene associations.

30 Genes

ABCB1, ABCG2, ANKK1, APOE, C11orf65, COMT, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, CYP4F2, DPYD, DRD2, Factor II, Factor V, GRIK4, HTR2A, HTR2C, ITGB3, MTHFR, NUDT15, OPRM1, SLCO1B1, TPMT, UGT2B15, VKORC1

Patients who are considering starting a medication therapy protocol or who are currently on a medication therapy protocol.

Price: $150.00

Test Details

Preemptive or reactive genotyping of patients for pharmacogenomic purposes to provide an assessment for 30 genes with strong drug-gene associations.

 

30 Genes

ABCB1, ABCG2, ANKK1, APOE, C11orf65, COMT, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, CYP4F2, DPYD, DRD2, Factor II, Factor V, GRIK4, HTR2A, HTR2C, ITGB3, MTHFR, NUDT15, OPRM1, SLCO1B1, TPMT, UGT2B15, VKORC1

Patients who are considering starting a medication therapy protocol or who are currently on a medication therapy protocol.

  • The patient has a history of medication failure.
  • The patient is starting a new medication, with no previous history.
  • The patient has a new diagnosis, with no pharmacological treatment history to treat that diagnosis.
  • The patient has a history of, or is currently experiencing, adverse side effects from his/her current medication(s).
  • The patient is on multiple medications, raising the risk for adverse drug reactions.
  • The patient is starting on oral contraceptives (drospirenone/ethinylestradiol) associated with a risk of venous thrombosis.
  • The patient has ACS, undergoing PCI and is initiating or reinitiating Clopidogrel (Plavix) therapy.
  • The patient is taking antithrombotic medications (e.g., Clopidogrel).
  • The patient is taking cardiovascular medications such as beta-blockers, antiarrhythmic drugs, or statins.
  • The patient is initiating therapy with amitriptyline or nortriptyline for treatment of depressive disorders.
  • The patient is initiating therapy with tetrabenazine doses greater than 50 mg/day, or re-initiation of therapy with doses greater than 50 mg/day.
  • The patient is taking psychiatric or neurological drugs (e.g., antidepressants, antipsychotics, anticonvulsants, mood stabilizers, or stimulants).
  • Dosing increases on current medications have had a sub-therapeutic response.
  • The patient has not complied with his/her current medication regimen due to adverse drug reactions.

The test results are necessary to:

  • Guide decisions about which medications to prescribe and/or avoid for this patient, or to guide decisions concerning dosing for current medication(s).
  • Identify possible alternative medications which may yield a better therapeutic response for this patient than he/she is currently experiencing.
  • Identify medications that should be avoided due to elevated risk of adverse effects for this patient.
  • Help manage this patient’s cardiovascular or thrombotic risk.
  • PCR
  • Next-Generation  Sequencing
  • Deletion/Duplication Analysis

Buccal Swab

1-2 weeks

81225, 81226